CI

At a glance

ClinicalIndex Comparison Record
Early Ph 1Completed· 30 enrolled
Drug / intervention
Vitamin D +1 moredrug
Likely dose
Vitamin D 400 unitsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06539260
NCT06539260Early Ph 1Completed
CompareCT.gov

Clinical Relationship Between Vitamin D-mediated Th17 and Treg Cells and Parkinson's Disease

Suzhou Municipal Hospital of Anhui Province·interventional·Posted Aug 6, 2024·Updated Aug 26, 2024

In Brief

A Early Phase 1 clinical trial evaluating Vitamin D and Placebo for Neurology and Immunology. Completed, enrolled 30 participants across 1 site.

Detailed Summary

The aim of this study is to detect the expression levels of vitamin D, Treg, and Th17 in the peripheral blood of patients with Parkinson\'s disease (PD), investigate the impact of Treg/Th17 imbalance on PD patients, and explore the effects of vitamin D intervention on Treg/Th17 imbalance and clinical outcomes. Furthermore, this study aims to delve into the potential mechanisms of vitamin D deficiency and Treg/Th17 imbalance in the pathogenesis of Parkinson\'s disease, ultimately providing new theoretical evidence for the research, prevention, and treatment of PD.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeurology, Immunology
CountriesChina
Collaborators--

Timeline

Early Ph 1CompletedFinished
2023202420252026
First PostedAug 6, 2024
Enrollment StartJan 1, 2023
Primary CompletionJul 1, 2024
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 1.9 years ago

Interventions

Vitamin Ddrug

Take 400 units of vitamin D3, twice daily, for a duration of 3 months.

Placebodrug

Take a placebo that is identical in appearance and weight to 400 units of vitamin D3, twice daily, for a duration of 3 months.